PMID: 8105597Jul 1, 1993Paper

Partial agonists, full agonists, antagonists: dilemmas of definition

Trends in Pharmacological Sciences
D Hoyer, H W Boddeke


The absence of selective antagonists makes receptor characterization difficult, and largely dependent on the use of agonists. However, there has been considerable debate as to whether certain drugs acting at G protein-coupled receptors are better described as agonists, partial agonists or antagonists. Indeed many agonists tend to display differences in intrinsic activity, depending on the preparation used to study receptor pharmacology. It has been argued that variations in intrinsic activity of drugs, may be a reflection of receptor subtypes rather than varying degrees of receptor-effector coupling. However, it has often been overlooked that classical receptor theory predicts that a drug acting at a given receptor type can display a range of intrinsic activities depending on the extent of receptor reserve. Furthermore, because any receptor can couple to different effector systems, different degrees of intrinsic activity may be observed for a given drug. Daniel Hoyer and Hendrikus Boddeke review recent data which provide explanations for why drugs display such variations in intrinsic activity.


Aug 1, 1986·Naunyn-Schmiedeberg's Archives of Pharmacology·R MarksteinG Engel


Aug 31, 2002·Molecular Reproduction and Development·M E Dell'AquilaP Minoia
Sep 19, 2002·Molecular Reproduction and Development·Herbert SchuelAlexandros Makriyannis
Sep 1, 1995·Psychopharmacology·K A MiczekH M Barros
Feb 24, 2005·Naunyn-Schmiedeberg's Archives of Pharmacology·S JähnichenHeinz H Pertz
Nov 16, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Heinz H PertzAndrea Strasser
Jan 1, 2010·Amino Acids·Mohammed Akhter HossainRoss A D Bathgate
Feb 5, 1996·European Journal of Pharmacology·G BonoL Pulvirenti
Dec 4, 1995·European Journal of Pharmacology·D M WalshH E Connor
Feb 22, 1996·European Journal of Pharmacology·E HeldmanZ Vogel
Sep 12, 1996·European Journal of Pharmacology·C C GerhardtH Van Heerikhuizen
Apr 1, 1995·Pharmacology & Therapeutics·S L Handley
Dec 1, 1993·Trends in Pharmacological Sciences·T Kenakin
Apr 1, 1994·Trends in Pharmacological Sciences·S M Hourani, D A Hall
Oct 1, 1994·Trends in Pharmacological Sciences·L Pulvirenti, George F Koob
Jul 1, 1994·Trends in Pharmacological Sciences·P R Albert, S J Morris
Jan 1, 1996·General Pharmacology·J F KlinkerRoland Seifert
Oct 15, 1995·European Journal of Pharmacology·M G CattaneoL M Vicentini
Oct 16, 2003·Trends in Pharmacological Sciences·Petrus J Pauwels
Mar 10, 2000·European Journal of Pharmacology·R H Alper, D L Nelson
Feb 12, 1997·European Journal of Pharmacology·J A Stanton, M S Beer
Sep 9, 1999·European Journal of Pharmacology·L K Chong, P T Peachell
Aug 31, 2001·Pharmacology, Biochemistry, and Behavior·E IzzoL Pulvirenti
Sep 19, 2003·Pharmacology, Biochemistry, and Behavior·Janet M SiboleSanders A McDougall
Jun 28, 2000·Journal of the Autonomic Nervous System·Eric A Barnard
Apr 5, 2002·Trends in Pharmacological Sciences·L Pulvirenti, George F Koob
Jan 26, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·A BrambillaF Borsini
Jan 27, 1999·Journal of Pharmacological and Toxicological Methods·V Calderone, E Martinotti
Aug 28, 1999·Journal of Pharmacological and Toxicological Methods·V Calderone, E Martinotti
Feb 8, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Seok-Joo ParkHyoung-Chun Kim
Aug 5, 1998·British Journal of Pharmacology·D E DruryP T Peachell
Sep 13, 1994·Proceedings of the National Academy of Sciences of the United States of America·B BertinS Marullo
Jun 1, 2012·The Journal of Biological Chemistry·Kamila BledzkaEdward F Plow
Apr 1, 1994·British Journal of Pharmacology·H YasumatsuM Setoguchi
Dec 1, 1995·British Journal of Pharmacology·L Eriksen, C Thomsen
Feb 22, 2012·Journal of Psychopharmacology·Floris KlumpersJohanna M P Baas
Nov 10, 2010·Naunyn-Schmiedeberg's Archives of Pharmacology·Beryl KoenerEmmanuel Hermans
Aug 26, 1999·Neuropharmacology·N M Barnes, T Sharp
Mar 1, 2011·Expert Opinion on Emerging Drugs·Anne J Lee, Ivan Goldberg
Jul 3, 2007·Expert Opinion on Emerging Drugs·David Woodward, June Chen
Oct 23, 2013·Pharmacological Reports : PR·Magdalena Jastrzębska-WięsekAnna Wesołowska
Jun 27, 2012·Drug Discovery Today·Masahiko Fujioka, Naoki Omori
Feb 2, 2010·Neurochemistry International·Luciano Minuzzi, Paul Cumming
Oct 6, 2009·Brain Research Bulletin·Rizângela Lyne Mendes de FreitasRivelilson Mendes de Freitas
Mar 25, 2009·Pharmacology & Therapeutics·Sarah Grimwood, Paul R Hartig
Dec 27, 2008·Pharmacology & Therapeutics·V J AloyoJ A Harvey
Jun 27, 2006·Biochemical Pharmacology·Joanna Dabrowska, Michal Brylinski
May 2, 2006·Pharmacology, Biochemistry, and Behavior·Michael E HoeferL Pulvirenti
Sep 13, 2005·Immunology Letters·Marie-Claude MathieuAlex G Therien
Aug 2, 2003·Biochemical and Biophysical Research Communications·Huifang GeMika Scheinin
Jan 1, 1996·Journal of Receptor and Signal Transduction Research·M D Pak, P H Fishman
Jan 1, 1997·Journal of Receptor and Signal Transduction Research·D Hoyer, P P Humphrey
Jan 1, 1995·Immunity·S C Jameson, M J Bevan
Jun 27, 2013·Psychiatry Investigation·Eunjin CheonJun-Yeob Lee
Jun 8, 2001·Reviews in the Neurosciences·L Pulvirenti, M Diana
Apr 11, 2017·Neuropharmacology·Carl R LupicaAlexander F Hoffman
Mar 25, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Michael J Hanley, George A Kenna
Apr 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·L CervoT Mennini
Mar 11, 2003·The Journal of Pharmacology and Experimental Therapeutics·Roland SeifertSigurd Elz
Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Kevin D BurrisPerry B Molinoff
Oct 1, 2018·The European Journal of Neuroscience·T Celeste Napier, Amanda L Persons
Jun 25, 2002·The Journal of Biological Chemistry·Joseph SimonEric A Barnard
Oct 16, 1999·The Journal of Clinical Endocrinology and Metabolism·J SandersB R Smith
Aug 27, 1999·Molecular Pharmacology·Q Yang, S M Lanier
May 16, 2017·Journal of Nanoparticle Research : an Interdisciplinary Forum for Nanoscale Science and Technology·Anna NiesciorukAleksandra Misicka
Dec 1, 2019·International Journal of Molecular Sciences·Emmanuel FenouilletJean Ruf
Jan 18, 2008·Journal of Medicinal Chemistry·Michael J MarinoMichael Williams

Related Concepts

HeLa Cells
Receptors, Tryptamine
Serotonin Antagonists
Dopamine Effect
Serotonin Agonists
Dopamine D2 Receptor
GTP-Binding Proteins

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Torsion Dystonia

Torsion dystonia is a movement disorder characterized by loss of control of voluntary movements appearing as sustained muscle contractions and/or abnormal postures. Here is the latest research.

Generating Insulin-Secreting Cells

Reprogramming cells or using induced pluripotent stem cells to generate insulin-secreting cells has significant therapeutic implications for diabetics. Here is the latest research on generation of insulin-secreting cells.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.

Epigenome Editing

Epigenome editing is the directed modification of epigenetic marks on chromatin at specified loci. This tool has many applications in research as well as in the clinic. Find the latest research on epigenome editing here.